Fifteen Years after Sleeve Gastrectomy: Gastroscopies, Manometries, and 24-h pH-Metries in a Long-Term Follow-Up: A Multicenter Study.


Journal

Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429

Informations de publication

Date de publication:
2022
Historique:
received: 06 05 2022
accepted: 30 06 2022
pubmed: 27 7 2022
medline: 27 10 2022
entrez: 26 7 2022
Statut: ppublish

Résumé

Sleeve gastrectomy (SG) is the most common bariatric operation with over 340,000 procedures per year. There are only few studies presenting follow-up results >10 years in the literature today. The aim of this study was the objective evaluation of long-term outcomes of at least 15 years after SG in non-converted patients. This study (multicenter cross-sectional; university-hospital based) includes all non-converted patients with primary SG before December 2005 at participating bariatric centers. The following methods were used: gastroscopy, esophageal manometry, 24-h pH-metry, and Gastrointestinal Quality of Life Index (GIQLI). After removing converted patients, patients with bariatric procedures before SG, and deceased patients from the cohort, 20 of 53 participants have met the inclusion criteria. Of this group, 55% are suffering from symptomatic gastroesophageal reflux disease (GERD); 45% are without GERD. Esophagitis, hiatal hernias, Barrett's esophagus, and enlarged sleeves were found in 44%, 50%, 13%, and 69% of patients during gastroscopy. Mean lower esophageal sphincter pressure was normal at 20.2 ± 14.1 mm Hg during manometry. Reflux activity in 24 h, number of refluxes, and DeMeester score were increased at 12.9 ± 9.7%, 98.0 ± 80.8, and 55.3 ± 36.3 during 24-h pH-metry. Patients with GERD scored significantly lower in the GIQLI than patients without GERD: 107.6 ± 18.4 versus 127.6 ± 14.4 (p = 0.04). Fifteen years after primary SG, objective testing has shown that GERD, esophagitis, and Barrett's esophagus are major issues for these patients. Surveillance endoscopies at 5-year intervals in all SG patients and 3-year intervals in patients with Barrett's esophagus are recommended.

Identifiants

pubmed: 35882187
pii: 000526170
doi: 10.1159/000526170
pmc: PMC9669976
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

666-673

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Références

Surg Obes Relat Dis. 2011 Jul-Aug;7(4):510-5
pubmed: 21130052
Surg Obes Relat Dis. 2017 Apr;13(4):568-574
pubmed: 28089434
Surg Obes Relat Dis. 2016 Dec;12(10):1778-1786
pubmed: 27178613
Surg Obes Relat Dis. 2021 Feb;17(2):329-337
pubmed: 33153961
Surg Endosc. 2015 Jul;29(7):1760-8
pubmed: 25303918
J Minim Access Surg. 2019 Jul-Sep;15(3):229-233
pubmed: 29974879
Obes Surg. 2019 Nov;29(11):3536-3541
pubmed: 31201693
Obes Surg. 2018 Oct;28(10):2991-2997
pubmed: 29931481
Obes Surg. 2021 May;31(5):1937-1948
pubmed: 33432483
Obes Surg. 2022 Jun;32(6):2079-2080
pubmed: 35412262
Obes Surg. 2018 Jan;28(1):130-134
pubmed: 28707172
Gastroenterology. 2011 Mar;140(3):1084-91
pubmed: 21376940
Obes Surg. 2021 Aug;31(8):3453-3461
pubmed: 34021882
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Obes Surg. 2010 May;20(5):535-40
pubmed: 20094819
Obes Surg. 2018 Nov;28(11):3586-3594
pubmed: 30047101
Surg Obes Relat Dis. 2008 Sep-Oct;4(5):575-9; discussion 580
pubmed: 18407801
Rom J Intern Med. 2021 Aug 26;59(3):296-302
pubmed: 33600675
Obes Surg. 2022 May;32(5):1617-1623
pubmed: 35278191
Surg Endosc. 2019 Mar;33(3):789-793
pubmed: 30003346
Clin Gastroenterol Hepatol. 2009 Jun;7(6):653-8; quiz 606
pubmed: 19264576
Obes Surg. 2012 Mar;22(3):360-6
pubmed: 22065341
Surg Obes Relat Dis. 2018 Oct;14(10):1480-1487
pubmed: 30093311
Obes Surg. 2020 Oct;30(10):3847-3851
pubmed: 32524524
Obes Surg. 2019 Mar;29(3):782-795
pubmed: 30421326
Obes Surg. 2005 Nov-Dec;15(10):1469-75
pubmed: 16354529
Obes Surg. 2017 Dec;27(12):3092-3101
pubmed: 28593484
Gastrointest Endosc. 2021 Feb;93(2):343-352.e2
pubmed: 32798535
Surg Technol Int. 2020 May 28;36:63-69
pubmed: 32359172
Obes Surg. 2019 Dec;29(12):3809-3817
pubmed: 31583514
Chirurg. 1993 Apr;64(4):264-74
pubmed: 8482141
Surg Obes Relat Dis. 2018 Jun;14(6):751-756
pubmed: 29571635
Obes Surg. 2017 Jul;27(7):1797-1803
pubmed: 28190216
Am J Gastroenterol. 2018 Aug;113(8):1148-1155
pubmed: 29880962

Auteurs

Daniel Moritz Felsenreich (DM)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Evi Artemiou (E)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Lukas Wintersteller (L)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Julia Jedamzik (J)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Jakob Eichelter (J)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Lisa Gensthaler (L)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Christoph Bichler (C)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Christoph Sperker (C)

Department of Surgery, Klinik Landstraße, Vienna, Austria.

Philipp Beckerhinn (P)

Department of Surgery, Landesklinikum Hollabrunn, Hollabrunn, Austria.

Ivan Kristo (I)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Felix Benedikt Langer (FB)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Gerhard Prager (G)

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH